Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Encequidar/paclitaxel - Hanmi Pharmaceutical

Next Previous
Drug Profile

Encequidar/paclitaxel - Hanmi Pharmaceutical

Alternative Names: HM-30181A/paclitaxel - Hanmi Pharmaceutical; HM30181AK; Oraxol; Paclitaxel+HM30181AK; Paclitaxel/encequidar - Hanmi Pharmaceutical; Paclitaxel/HM-30181A - Hanmi Pharmaceutical; Paclitaxel/HM30181-methanesulfonate monohydrate - Hanmi Pharmaceutical

Latest Information Update: 02 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Athenex; Hanmi Pharmaceutical; PharmaEssentia Corporation; Zenith Technology Corporation
  • Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma; Haemangiosarcoma
  • New Molecular Entity No

Highest Development Phases

  • Registered Breast cancer
  • Phase II Cancer; Gastric cancer; Haemangiosarcoma
  • Phase I Solid tumours
  • No development reported Oesophageal cancer

Most Recent Events

  • 02 Jun 2023 Adverse events and efficacy data from a phase II trial in Breast cancer (Neoadjuvant therapy, Combination therapy, Late-stage disease) presented at 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 22 May 2023 Athenex terminates a phase I trial in Solid tumours (Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in United Kingdom (PO), due to financial constrains (NCT03892018)
  • 12 May 2023 Athenex terminates a phase I clinical trial in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03588039)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top